Christine M. Walko

Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study

William Irvin, Christine M. Walko, Karen E. Weck et al. · Journal of Clinical Oncology · 2011 · 179 citations

Medicine, Pharmacokinetics, Pharmacology +17

Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (Herceptin®) and Irinotecan as Therapy. A Phase II Trial

Ramesh K. Ramanathan, Jimmy J. Hwang, William C. Zamboni et al. · Cancer Investigation · 2004 · 138 citations

Medicine, Oncology, Pharmacokinetics +14

Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays

Catherine C. Coombs, Nancy Gillis, Xianming Tan et al. · Clinical Cancer Research · 2018 · 123 citations · Full text

Medicine, Hematology, Oncology +17

Tumor Mutation Burden and Cancer Treatment

Michael Fusco, Howard West, Christine M. Walko · JAMA Oncology · 2020 · 111 citations

Medicine, Cancer Biology, Oncology +14

Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study

Solmaz Sahebjam, Peter Forsyth, Nam Tran et al. · Neuro-Oncology · 2020 · 109 citations · Full text

Medicine, Oncology, Pharmacotherapy +17